Analyst Reco. Genmab A/S

Equities

GMAB

DK0010272202

Biotechnology & Medical Research

Market Closed - Nasdaq Copenhagen Other stock markets 08:50:00 10/04/2026 pm IST			5-day change	1st Jan Change
1,790.00 ^DKK	-0.69%		+1.79%	-11.69%

10/04	Nordic Equities in North America - Ericsson slips 0.5 percent	FW
09/04	Nordic Equities in North America - Autoliv slips 0.7 percent	FW

Analyst Reco.

23/03	H. Lundbeck Price Target Down as AlphaValue/Baader Europe Expects Patent Expirations to Weigh on Growth	MT
06/03	UBS Lowers Price Target for Genmab to 2,600 Danish Kroner (from 2,750), Reiterates Buy	FW
04/03	SHB Sees Multiple Potential Share Price Triggers for Genmab, Raises Target Price	FW
03/03	Handelsbanken Raises Genmab Price Target to 2,220 Danish Kroner (from 2,200), Reiterates Buy - BN	FW
23/02	Bernstein Raises Price Target for Genmab to 1,400 Danish Kroner (from 1,015), Reiterates Underperform - BN	FW
19/02	BofA Bullish on Genmab's FY26 Catalyst Path; Buy Rating Maintained	MT
18/02	Genmab: 2025 miss and cautious 2026 targets erode investor confidence
18/02	DNB Carnegie Raises Target Price for Genmab to 2,300 Danish Kroner (from 2,235), Reiterates Buy Recommendation	FW
18/02	Goldman Sachs Lowers Price Target for Genmab to 1,771 Danish Kroner (from 1,793), Reiterates Neutral Rating - BN	FW
17/02	Jefferies Resumes Coverage of Genmab with Buy Rating, Citing Attractive Valuation Case	FW
17/02	Jefferies Resumes Coverage of Genmab with Buy Rating and Price Target of 2,650 Danish Kroner	FW
04/02	Goldman Sachs Lowers Price Target for Genmab to 1,793 Danish Kroner (from 1,880), Reiterates Neutral - BN	FW
21/01	DNB Carnegie Upgrades Genmab to Buy, Raises PT	MT
21/01	DNB Carnegie Upgrades Genmab to Buy (Hold), Raises Target Price to 2,235 Danish Kroner (from 1,985)	FW
20/01	BofA Lifts Genmab Price Target, Estimates on Expected 'Catalyst Rich' FY26	MT
19/01	SHB: Overreaction in the Market to Genmab's Epkinly Study	FW
15/01	Jyske Bank Raises Genmab Target Price to 2,300 Danish Kroner (2,000), Reiterates Hold - BN	FW
08/01	UBS Raises Price Target for Genmab to 2,750 Danish Kroner (from 2,700), Reiterates Buy	FW
30/12	Genmab Faces 'Transformative' Year Ahead With Pivotal Trial Readouts, Truist Securities Says	MT
30/12	Genmab Kept at Buy as Truist Securities Forecasts 'Transformative' Year Ahead	MT
30/12	DNB Carnegie Trims Genmab PT, Maintains Hold Rating	MT
30/12	SHB: Genmab's Decision to Halt Acasunlimab Development Deemed Logical	FW
30/12	DNB Carnegie Lowers Price Target for Genmab to 1,985 Danish Kroner (from 2,050), Reiterates Hold	FW
19/12	Deutsche Bank Raises Target Price for Genmab to 2,400 Danish Kroner (2,000), Reiterates Buy	FW
08/12	JP Morgan Raises Genmab Price Target to 2,050 Danish Kroner (from 1,650), Maintains Neutral Rating - BN	FW